Subscribe to RSS
DOI: 10.1055/s-0042-115172
Intravenous injection of low-dose flurbiprofen axetil for preventing post-ERCP pancreatitis in high-risk patients: An interim analysis of the trial
Publication History
submitted25 September 2015
accepted after revision29 July 2016
Publication Date:
21 September 2016 (online)
Background and study aims: Several meta-analyses and randomized control trials have demonstrated the efficacy of rectal nonsteroidal anti-inflammatory drugs for preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Diclofenac or indomethacin was administered at a dose of 100 mg in those studies, which may be too high for Asian population. In addition, rectal administration can be considered complicated.
Patients and methods: This study was a prospective, randomized, placebo-controlled trial. Patients with a PEP risk score ≥ 1 were randomly assigned to receive intravenous injection of 50 mg flurbiprofen axetil (flurbiprofen group) or saline only (placebo group). The primary outcome was reduced PEP. The secondary outcome was amylase level after 2 hours of ERCP as a predictor of PEP. (Clinical Trials.gov, ID UMIN000011322)
Results: In total, 144 patients were enrolled from August 2013 to March 2015. We performed an interim analysis of the first 100 patients: 47 received flurbiprofen axetil and 53 received placebo. PEP occurred in 11 patients (11 %): 2 of 47 (4.3 %) in the flurbiprofen group and 9 of 53 (17 %) in the placebo group (P = 0.042). Relative risk reduction was 62.4 %. Hyperamylasemia did not differ significantly (17.0 % vs. 26.4 %, P = 0.109). This analysis resulted in early termination of the study for ethical reasons.
Conclusions: Intravenous injection of low-dose flurbiprofen axetil after ERCP can reduce the incidence of PEP in high-risk patients
-
References
- 1 Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 3 83-393
- 2 Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918
- 3 Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434
- 4 Gottlieb K, Sherman S. ERCP and endoscopic biliary sphincterotomy-induced pancreatitis. Gastrointest Endosc Clin N Am 1998; 8: 87-114
- 5 Freeman ML. Adverse outcomes of ERCP. Gastrointest Endosc 2002; 56: 273-282
- 6 Elmunzer BJ, Scheiman JM, Lehman GA et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
- 7 Rabenstein T, Hahn EG. Post-ERCP pancreatitis: new momentum. Endoscopy 2002; 34: 325-329
- 8 Vandervoort J, Soetikno RM, Tham TC et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56: 652-656
- 9 Whitcomb DC. Acute pancreatitis: molecular biology update. J Gastrointest Surg 2003; 7: 940-942
- 10 Gross V, Leser HG, Heinisch A et al. Inflammatory mediators and cytokines: new aspects of the pathophysiology and assessment of severity of acute pancreatitis?. Hepatogastroenterology 1993; 40: 522-530
- 11 Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997; 57: 401-407
- 12 Murray B, Carter R, Imrie C et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124: 1786-1791
- 13 Sotoudehmanesh R, Khatibian M, Kolahdoozan S et al. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 2007; 102: 978-983
- 14 Khoshbaten M, Khorram H, Madad L et al. Role of diclofenac in reducing postendoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol 2008; 23: e11-16
- 15 Montaño Loza A, Rodríguez Lomelí X, García Correa JE et al. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev Esp Enferm Dig 2007; 99: 330-336
- 16 Elmunzer BJ, Higgins PD, Saini SD et al. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol 2012; 108: 410-415
- 17 Otsuka T, Kawazoe S, Nakashita S et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol 2012; 47: 912-917
- 18 Hofbauer B, Saluja AK, Lerch MM et al. Intra-acinar cell activation of trypsinogen during cerulean-induced pancreatitis in rats. Am J Physiol 1998; 275: G352-362
- 19 Messmann H, Vogt W, Holstege A et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997; 40: 80-85
- 20 Karne S, Gorelick FS. Etiopathogenesis of acute pancreatitis. Surg Clin N Am 1999; 79: 699-710
- 21 Bhatia M, Brady M, Shokuhi S et al. Inflammatory mediators in acute pancreatitis. J Pathol 2000; 190: 117-125
- 22 Elmunzer BJ, Waljee AK, Elta GH et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-1267
- 23 Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal anti-inflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy 2005; 25: 18-25
- 24 Yuhara H, Ogawa M, Kawaguchi Y et al. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis. J Gastroenterol 2014; 49: 388-399
- 25 Working Group JPS . Post ERCP Pancreatitis Guidelines 2015. Suizou 30: 539-584
- 26 Higashino M, Konishi Y, Kojima H et al. 83 single and human blood concentration at the time of continuous intravenous administration transition and metabolism. Kiso to Rinsho 1992; 26: 3907-3921
- 27 Cennamo V, Fuccio L, Zagari RM et al. Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis? A meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 2343-2350
- 28 Nambu T, Ukita T, Shigoka H et al. Wire-guided selective cannulation of the bile duct with a sphincterotome: a prospective randomized comparative study with the standard method. Scand J Gastroenterol 2011; 46: 109-115
- 29 Kawakami H, Maguchi H, Mukai T et al. A multicenter, prospective, randomized study of selective bile duct cannulation performed by multiple endoscopists: the BIDMEN study. Gastrointest Endosc 2012; 75: 362-372
- 30 Kobayashi G, Fujita N, Imaizumi K et al. Wire-guided biliary cannulation technique does not reduce the risk of post-ERCP pancreatitis: multicenter randomized controlled trial. Dig Endosc 2013; 25: 295-302